Product logins

Find logins to all Clarivate products below.


Blog: Regulatory

Here you will find relevant articles and insight into all Clarivate related products and news.

Tracking the mid-year momentum of the 2026 Drugs to Watch Tracking the mid-year momentum of the 2026 Drugs to Watch
Blog July 8, 2026
Tracking the mid-year momentum of the 2026 Drugs to Watch
Biopharma Biotech Clinical trials
BioWorld: celebrating recognition, reaffirming our mission BioWorld: celebrating recognition, reaffirming our mission
Blog July 1, 2026
BioWorld: celebrating recognition, reaffirming our mission
Biopharma Dealmaking M&A
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech
Europe looks to shore up global competitiveness with the E.U. Biotech Act Europe looks to shore up global competitiveness with the E.U. Biotech Act
Blog June 22, 2026
Europe looks to shore up global competitiveness with the E.U. Biotech Act
Biopharma Biotech Business Development
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials
De-risking next-generation bispecific antibodies: a target-centric approach to safety intelligence De-risking next-generation bispecific antibodies: a target-centric approach to safety intelligence
Blog June 9, 2026
De-risking next-generation bispecific antibodies: a target-centric approach to safety intelligence
Bispecific antibodies BsAb Clinical trials
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
The competitive signals hiding in plain sight for biopharma The competitive signals hiding in plain sight for biopharma
Blog May 8, 2026
The competitive signals hiding in plain sight for biopharma
Biopharma Business Development Clinical trials

Regulatory

온디맨드 웨비나 사이트런칭 온디맨드 웨비나 사이트런칭
Blog March 15, 2022
온디맨드 웨비나 사이트런칭
Tracking the mid-year momentum of the 2026 Drugs to Watch Tracking the mid-year momentum of the 2026 Drugs to Watch
Blog July 8, 2026
Tracking the mid-year momentum of the 2026 Drugs to Watch
BioWorld: celebrating recognition, reaffirming our mission BioWorld: celebrating recognition, reaffirming our mission
Blog July 1, 2026
BioWorld: celebrating recognition, reaffirming our mission
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Europe looks to shore up global competitiveness with the E.U. Biotech Act Europe looks to shore up global competitiveness with the E.U. Biotech Act
Blog June 22, 2026
Europe looks to shore up global competitiveness with the E.U. Biotech Act
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
De-risking next-generation bispecific antibodies: a target-centric approach to safety intelligence De-risking next-generation bispecific antibodies: a target-centric approach to safety intelligence
Blog June 9, 2026
De-risking next-generation bispecific antibodies: a target-centric approach to safety intelligence
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
The competitive signals hiding in plain sight for biopharma The competitive signals hiding in plain sight for biopharma
Blog May 8, 2026
The competitive signals hiding in plain sight for biopharma
Target selection and safety assessment: Navigating early decisions that shape drug development Target selection and safety assessment: Navigating early decisions that shape drug development
Blog March 27, 2026
Target selection and safety assessment: Navigating early decisions that shape drug development
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers